

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 76-422

APPROVAL LETTER

ANDA 76-422

Altana Inc.
Attention: Audrey Zaweski
60 Baylis Road
Melville, NY 11747

AUG 06 2004

Dear Madam:

This is in reference to your abbreviated new drug application dated May 28, 2002, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (Act), for Ciclopirox Topical Suspension USP, 0.77% (LOTION).

Reference is also made to your amendments dated April 24, 2003; January 22 (two amendments), February 2, and August 4, 2004.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the application is approved. The Division of Bioequivalence has determined your Ciclopirox Topical Suspension USP, 0.77% (LOTION) to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Loprox[®] Topical Suspension, 0.77% of Medicis Pharmaceutical Corp.).

Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.


Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration
Division of Drug Marketing, Advertising, and Communications,
HFD-42
5600 Fishers Lane
Rockville, MD 20857

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-40) with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours,

A handwritten signature in dark ink, appearing to read "Gary Buehler", with a stylized, cursive script.

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

cc: ANDA 76-422
Division File
Field Copy
HFD-610/R. West
HFD-330
HFD-205
HFD-610/Orange Book Staff

Endorsements:

HFD-629/L.Huang/ *L Huang 6/15/04*
HFD-623/J.Fan/ *6/13/04* *6/15/04* *7/8/04*
HFD-617/T.Vu/
HFD-613/B.Weitzman/ *6/21/04*
HFD-613/J.Grace/ *6/21/04* *8/6/04*

\\Cds013\OGDS11\FIRMSAM\ALTANA\LTRS&REV\76422.ap.doc
\\CDS013\OGDS11\FIRMS
F/T by

APPROVAL

PS 7/13/04